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Summary
Introduction Erythema nodosum leprosum (ENL) is an inflammatory reaction,
which may occur in the course of leprosy and may result in nerve function
impairment and subsequent disability.
Methods This retrospective study explores demographic and disease specific
parameters. Severity of ENL was assessed using the Reaction Severity Scale (RSS).
Records of 94 patients were reviewed. The study reports also on the treatment of 76 of
these patients who were treated with prednisolone alone or thalidomide in addition to
prednisolone.
Results Thirty percent of patients presented with ENL at time of diagnosis; 41%
developed ENL-reaction in the first year of MDT. Forty-eight percent of patients
were treated for ENL-reaction for less than 12 months; 13% for more than 5 years.
High RSS-scores correlated with a longer duration of treatment. In group A
(prednisolone) 51·7% and in group B (prednisolone and thalidomide) 76·6% of
patients were male. Age, leprosy classification, delay of multidrug treatment (MDT)
and interval between MDT and first ENL-symptoms did not differ significantly in
both groups. Median duration of ENL-treatment was 15 months in group A versus
38 months in group B (P , 0·001). At the start of treatment, ENL-reaction was less
severe in group A (RSS ¼ 12) than in group B (RSS ¼ 18; P ¼ 0·003).
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Discussion ENL-symptoms may be of help in the early diagnosis and adequate
treatment of ENL. Characterisation of (sub) groups of patients with ENL based on
presence and severity of symptoms is important for future prospective studies to
better evaluate the efficacy of interventions.
Introduction
Leprosy is an infectious disease affecting mainly the skin, by invasion of histiocytes, and
the nerves by invasion of Schwann-cells. The latter process may lead to irreversible nerve
function impairment (NFI) and subsequent chronic disabilities. In 2004, nearly 7000 new
cases were detected in Nepal, a country with high endemicity of leprosy.1
Erythema nodosum leprosum (ENL), or type 2 reaction, is an acute inflammatory
condition involving a TNF-a- and immune complex mediated immune response with
infiltration with Th2-cells, that occurs most frequently in LL-patients, less frequently in BL
patients and is more commonly seen in patients with a high bacterial index.2,3 ENL-reaction
may occur during or after treatment but may also be the presenting feature in new patients
presenting for diagnosis.3,4 Clinical symptoms include the typical crops of small painful red
nodules on the skin. Other organs that can be involved in this systemic reaction are lymph
nodes, liver, kidneys, spleen, nerves, eyes, testis and joints.5,6 Chronic and recurrent ENL
may last for months or years and may cause chronic neuropathy and disability or even death if
left untreated.7 – 10 Saunderson also found that ENL-reaction is an important risk factor for
chronic and recurrent neuropathy, with a relative risk of 11·6 (3·1–43).
Although immunological reactions are very common and are considered a major source of
morbidity in leprosy, little data has been published on the epidemiology of ENL. Manandhar et al.
published an epidemiological study which included 108 ENL-patients.11 In 2004, Kumar
reported on 2600 leprosy patients, of which 885 developed ENL-reaction and in 2006 Pocaterra
reported on 116 patients.2,12 Other studies included much smaller numbers of patients with
ENL.4,13,14 Thalidomide is an effective drug in treating the skin and systemic features of ENL,
leading to rapid improvement. This has been shown in several double-blind clinical studies.15–19
Its main adverse effects are teratogenicity and neurotoxicity.20–24 Because of these effects, some
countries and programmes will not, or can not, import or supply the drug.20,21,25,26 When used, it
should be prescribed under strict precautions to prevent the unwanted side-effects.20,22,27–29 The
drug’s mechanism of action is anti-inflammatory and thought to be through the selective
inhibition of the production of the pro-inflammatory cytokine TNF-a by monocytes.
In Green Pastures Hospital and Rehabilitation Centre (GPH&RC), thalidomide is used as
a second line drug: a) for patients suffering from chronic ENL; b) when high prolonged dose
of prednisolone do not control the reaction; c) when patients develop side-effects to
prednisolone, or d) when prednisolone is contra-indicated. The main aims of this study
were: a) to determine the clinical features of ENL in this group of patients, b) to report on
treatment outcome with prednisolone and thalidomide.
Methods and Patient Population
This was a retrospective study conducted at the Green Pastures Hospital and Rehabilitation
Centre (GPH&RC) in Pokhara, Nepal. This is a referral hospital, run by the International
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Nepal Fellowship (INF), that provides medical care for all leprosy patients in the Pokhara
region and for referred patients from Western Nepal. All patients with new ENL, both in- and
outpatient, registered at the GPH&RC neuritis clinic between April 15th 1996 and April 14th
2004 were included (n ¼ 94).
Twenty-nine patients with ENL were treated with prednisolone only (group A). Sixty five
patients also received thalidomide. Patients receiving thalidomide for mild ENL without
Nerve Function Impairment (NFI) (n ¼ 12) and patients with side-effects of prednisolone
(n ¼ 2) or with contra-indications for prednisolone (n ¼ 4) were excluded from the
analysis. Contra-indications and side-effects included diabetes mellitus, gastro-intestinal
bleeding, and tuberculosis. We reviewed the charts of the remaining 47 patients who received
thalidomide following the development of new ENL-nodules on prednisolone (group B,
n ¼ 47). Demographic characteristics, symptoms, clinical course and treatment outcomes of
group A were compared to group B to identify predictive factors for success of prednisolone-
treatment. Relevant bio-data, and patients’ disease and treatment characteristics were
extracted from the medical records.
CASE DEFINITIONS
Case definition of ENL. The appearance of typical erythematous skin lesions was the diagnostic
criterion for ENL, with or without other less specific symptoms such as fever or neuritis. Patients
with possible ENL-related symptoms but without the typical skin lesions were excluded.
Management of ENL. The standard treatment regimen consisted of 40 mg per day
prednisolone, tapering off within 16 weeks. Recurrent severe ENL was additionally treated
with higher doses of prednisolone up to 60 mg daily, clofazimine and/or thalidomide. Some
patients with mild ENL received only thalidomide usually as monotherapy. All patients
receiving thalidomide were treated as inpatients and female patients were put on strict
contraceptive medication.
Severity of ENL. Data were taken from patients’ charts and were scored according the
Reaction Severity Scale (RSS, appendix), excluding the reversal reaction related items, thus
leading to a maximum score of 74.This scale was a ‘trial scale’ and is different from the scale as
recently published in this journal which evolved from the scale used in our study.30 RSS-scores
were calculated at the start and the end of ENL-treatment. The RSS-high-score was calculated
by adding the highest scores of each RSS-item at any time during ENL-treatment.
Nerve function assessment. Standard nerve function assessment was conducted monthly,
and consisted of Voluntary Muscle Test (VMT) and Sensory Testing (ST). Sensory testing
was performed with the Semmes-Weinstein monofilaments and motor function was scored
according the Medical Research Council-scale.31,32
Nerve function impairment (NFI). This term described impaired sensory or motor nerve
function at nerve function assessment. Recent loss was considered to be loss of less than
6 months duration. Impairment was defined as follows: VMT for any muscle grade 4 or less;
ST see appendix RSS.
Nerve palpation findings (NPF). We used this term for what is often referred to as
‘neuritis’: enlarged or tender nerves on physical examination. We chose this term to prevent
confusion with ‘neuritis’, which is sometimes also used for nerve function impairment.
Duration of ENL. To assess the duration of ENL, the dates from start to end of treatment
with prednisolone and/or thalidomide were taken, thus including symptom-free periods.
In this study, no distinction was made between chronic and recurrent ENL.
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STATISTICAL ANALYSIS
The median duration of ENL treatment was estimated by using the Kaplan–Meier procedure
for censored survival data. Paired t-test was used to investigate the difference in severity of
ENL-reaction between the start and the end of treatment. Simple linear regression analysis
and the Pearson correlation coefficient were used to inspect the association between duration
of ENL treatment and the RSS. To assess the significance of differences in incidence of
symptoms in various groups, logistic regression is used. Significance of differences in
percentages of dichotomous observations is assessed with the Chi square test or the Fisher
exact test when appropriate.
To compare normally distributed variables the t-test for independent groups was used; for
non-normally distributed variables Mann–Whitney U was used. The log rank test was used to
compare Kaplan–Meier survival curves. P-values less than 0·05 are considered to indicate
significance. Statistical analysis of our data was performed using SPSS 14.0.
Results
CHARACTERISTICS OF ENL-PATIENTS
We reviewed the charts of 94 patients; 64 were male (68%). The age range was 11–70 with a
median of 35 years (25th percentile: 26 years, 75th percentile: 45 years). Most patients had
polar lepromatous leprosy (81%); BL leprosy was recorded in 19% of the patients. In one
patient, referred some years after MDT treatment, the classification could not be determined.
The time between the onset of the first leprosy symptoms and start of MDT ranged from
1 month to 24 years (Figure 1). Only 48% of the patients were diagnosed within the first year
after the first symptoms appeared; 20% within the first 6 months.
Approximately 30% of patients presented with ENL at the time of diagnosis (Figure 2).
Most patients (41%) developed ENL in the first year of treatment.
The duration of ENL could only be calculated in 63 cases, because both the date of the
start and the end of ENL-treatment need to be known. In these patients duration of treatment
ranged from 1 to 62 months. Fifteen patients were still on treatment after the closing date for
intake of the study; in eight patients, the end of treatment was unknown because of referral to
other treatment centres; two patients were lost to follow-up; in three cases (3%) treatment
with prednisolone/thalidomide extended for longer than 5 years. To indicate median duration
of ENL reaction, a Kaplan–Meier survival curve is presented in Figure 3.
Figure 1. Delay in diagnosis; time between first leprosy symptoms and start of MDT (n ¼ 87).
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The data contains 63 true measurements of which both starting date and final date of
ENL-treatment are recorded, and 25 censored measurements of which the starting date is
known but the patient was still on treatment at the last visit to the hospital. Censored
measurements are measurements of patients who were still on treatment at the end of the
study, patients referred while still on treatment or patients lost to follow up. Missing values
(n ¼ 6) are patients of which the starting date of the treatment is unknown. The estimated
median duration of ENL is 30 months (95% confidence interval 21–39 months). The figure
shows the survival of ENL-reaction, starting with all included measures at time ¼ 0
(cumulative survival ¼ 1) and decreasing as ENL-reactions subside.
Figure 2. Relationship of ENL onset to treatment with multi-drug therapy (n ¼ 88). Year refers to year since
starting MDT.
Figure 3. Kaplan–Meier curve for the duration of ENL. The line represents for each duration of treatment the
proportion of patients still on treatment for ENL. þ : censored observations (see also text). The dotted lines
correspond to the median duration of ENL: 50% of the patients experience ENL for more than 30 months.
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The severity of the ENL-reaction was assessed at the start and the end of ENL-treatment
using the Reaction Severity Scale. We also calculated the ‘RSS-high score’, the sum of all the
highest scores of each item of the RSS (Table 1).
We calculated this to indicate the severity of ENL, including all symptoms that were
noted during the reaction. The mean scores and the standard deviation are summarised and
the P-values given which show that mean RSS-score was lower at the end of treatment. This
decrease in RSS, calculated over the 71 patients with known RSS scores at start and end of the
ENL treatment, was 5·2 units on the RSS scale (95% confidence interval 3·9–6·6 RSS units).
Only 10 of 72 cases for whom the relevant data were available recovered completely
(RSS ¼ 0 at the end of ENL-treatment).
Figure 4 gives a scatter plot with a linear regression line, indicating a positive association
between severity of the ENL reaction (RSS-high score) and duration of ENL: Pearson
correlation coefficient ¼ 0·64, P , 0·001. For this calculation only the 63 cases with known
starting date and final date of ENL-treatment could be used.
FEATURES OF ENL-REACTION
The diagnosis of ENL-reaction largely depends on the appearance of ENL-skin lesion,
although the reaction often has systemic features and systemic involvement. Figure 5 shows
the prevalence of symptoms of ENL-reactions as measures in our group.
The prevalence of orchitis was calculated from data of only male patients (n ¼ 64). Missing
data per symptom varied from two to five. The prevalence of symptoms in male and female patients
or BL and LL patients did not differ significantly. The prevalence of symptoms was also calculated
by age groups: 14 (15%) cases were under 20 years of age at presentation; 43 (46%) were 20 to 39
years old; 32 (34%) patients were 40 to 59 years and five patients were over 60 years old.
Age-related differences are noticeable in low prevalence of fever (P ¼ 0·0086) in patients
over 60 years, and the increase of oedema (P ¼ 0·0332) with age. In the age groups,20 years,
20–39 years, 40–59 years and.60 years, the prevalence of fever was 58%, 91%, 76% and 20%
respectively and the prevalence of oedema was 33%, 65%, 83% and 80% respectively.
TREATMENT OUTCOME
Group A (n ¼ 29) included patients receiving prednisolone and group B (n ¼ 47) included
patients receiving thalidomide in addition to prednisolone because of insufficient response to
prednisolone.
Table 1. Severity of ENL-reaction, as measured by Reaction Severity Scale (RSS), at start and end of ENL-treatment
and RSS-high score during treatment
n Mean SD P-value*
RSS at start of treatment 85 16 8·6 ,0·001
RSS at end of treatment 72 7·4 6·0
RSS-high score** 89 29·8 11·3
* P-value resulting from paired t-test for the mean decrease in RSS in the 71 patients with known RSS scores at start
and end of ENL-treatment.
** RSS-high score: sum of the maximum scores per item during ENL-treatment period.
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Characteristics of groups. The groups differed in gender composition: 52% male patients
in group A versus 77% in group B (P ¼ 0·025) (Table 2).
There was no significant difference in age. In group A more patients were classified as BL
(34·5% versus 15·2%; P ¼ 0·052). Delay of leprosy treatment with MDT was longer in
group A (16 and 11 months respectively; P ¼ 0·097). The median time between the start of
Figure 4. Severity and duration of ENL-reaction. The severity of the ENL-reaction is given by means of the RSS high
score which is defined as the sum of the highest scores of each RSS-item and is displayed on the vertical axis. This
plot is based on the 63 cases with known start- and end-date of ENL. The line represents the linear regression line of
RSS high score on ENL duration. Pearson correlation ¼ 0·64, P , 0·001.
Figure 5. Incidence of symptoms; percentage of patients with specific sypmtoms.
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MDT and the first symptom of ENL differed, but not significantly: 12 months in group A, 5 in
group B (P ¼ 0·203). In both groups, ENL occurred in 1 out of 3 patients before MDT was
started.
Duration of ENL. Figure 6 shows survival curves for the length of ENL in each group,
starting with all included measures at time 0 (cumulative survival ¼ 1) and decreasing as
ENL reactions subside.
The data contains 49 true measurements of which both starting date and final date of
ENL-treatment are recorded, and 23 censored measurements of which the starting date is
known but the patient was still on treatment at the last visit to the hospital. Censored
measurements are measurements of patients who were still on treatment at the end of the
study, patients referred while still on treatment or patients lost to follow up. Missing values
(n ¼ 4) are patients of which the starting date of the treatment is unknown. Group A contains
9 censored measures and two missing values and group B, 14 and 2 respectively. Significance
is calculated using log rank test: P , 0·001.
Reaction severity. Table 3 shows that severity of ENL differed at start of ENL-treatment;
in group A, median RSS was 12, compared to group B, in which median RSS was 18
(P ¼ 0·003). The difference of severity at the end of treatment was not significant: in group
A, median RSS was four and in group B, median RSS was 11 (P ¼ 0·092). The RSS-high
score in group A was 21 and differed significantly from the RSS high score in group B, which
was 36 (P , 0·001).
Table 4 shows the differences in frequency of symptoms in both groups, pointing to
significant higher incidence of most symptoms in group B, except nerve palpation findings,
uveitis and orchitis.
To compare the effect of treatment in both groups, notes on ENL-skin lesions, NFI, NPF,
RSS and fever at end of ENL-treatment of both groups were compared to those at the start of
ENL-treatment (Table 5). The differences of treatment outcomes between the groups remain
non-significant.
Table 2. Characteristics of patients treated with thalidomide- and non-thalidomide regimens
Variable Group A (n ¼ 29) Group B (n ¼ 47) P-value
Sex
Male 51·7% 76·6% 0·025
Female 48·3% 23·4%
Age (years)
Mean (SD) 37·6 (12·5) 36·8 (13·1) 0·79
Classification (%)
BL 34·5% 15·2% 0·052
LL 65·5% 84·8%
Delay (months)
Median (25%–75%-ile) 16 (9–48) 11 (6–34) 0·097
Start ENL after start MDT in
months
Median (25%–75%-ile) 12 (0–27) 5 (0–12) 0·203
* % ENL at start MDT 33 33
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Discussion
The patients in this study may be unrepresentative of patients with ENL in general because
patients with severe ENL are more likely to be referred to a specialist centre. Our group also
includes patients that did not respond well to treatment with prednisolone, which also may be
indicative of more severe ENL. Mild reactions may also not be recognised and treated at a
local health post or hospital. The threshold to seek health care was also influenced by the
Maoist insurgency, poverty and limited availability of health care in rural areas.
One problem in (clinical) research in leprosy can be the confusing terminology. The term
‘neuritis’ is often used for both painful or enlarged nerves on physical examination, which we
Figure 6. Kaplan–Meier survival curves of duration of ENL. Solid line: group A; dotted line: group B; þ : censored
observation. The lines represent for each duration of t months of ENL the proportion of patients in group A,
respectively group B, that experience ENL for more than t months. The curve for patients treated with prednisolone
(group A) is below the curve for patients treated with prednisolone and thalidomide (group B), indicating a lower
proportion of patients with ENL at any point in time after the beginning of ENL (log rank test: P , 0·001).
Table 3. Differences in Reaction Severity Score in both groups (P values obtained by Mann–Whitney U test)
Group A (n ¼ 29) Group B (n ¼ 47)
RSS Median 25th–75th percentile Median 25th–75th percentile P-value
At start of treatment 12 10–17 18 13–23 0·003
At end of treatment 4 3–8 11 3–14 0·092
RSS-high score 21 14–25 36 30·5–42 ,0·001
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refer to as ‘Nerve Palpation Findings’, but also for NFI. In the literature there are also
different definitions of ENL-reaction. Van Brakel defined ENL as ‘: : : crops of tender
subcutaneous skin lesions’.33 For communication and research purposes there should be a
common understanding about terms being used.
CHARACTERISTICS OF ENL-PATIENTS
The gender ratio in our group is similar to other clinical studies with a male:female ratio of
2:1.20,34 Thus gender does not seem to be a risk factor for developing ENL. This contrasts
with a study from North India which showed that female patients were at a higher risk (male
RR ¼ 0·75 (0·59–0·95)), but concurs with two other studies in which gender was not found
Table 4. Incidence of symptoms in both groups
Group A Group B
Symptoms % n % n P-value
NPF 96 25 100 47 0·347
NFI 76 25 96 46 0·019
Fever 56 25 89 47 0·001
Joint pain 57 28 94 47 ,0·001
Oedema 40 28 74 47 0·004
Nerve pain 21 28 66 47 ,0·001
Eye involvement 11 28 53 47 ,0·001
Uveitis 7 28 19 47 0·158
Bone pain 14 28 49 47 0·002
Lymphadenitis 4 28 28 47 0·010
Orchitis 13 15 31 36 0·297
Muscle pain 0 28 15 47 0·041
P values obtained by logistic regression analysis (NPF: Nerve Palpation Findings. NFI: Nerve Function
Impairment).
Table 5. Comparison of progress during treatment of both groups on different items of Reaction Severity Scale
(P values based on t tests for independent groups)
N Better % Equal % Worse % Mean progress on RSS scale P-value
Skin
Group A 21 90 10 0 2·05 0·34
Group B 36 89 6 6 2·56
NFI
Group A 21 29 57 14 0·52 0·07
Group B 36 11 64 25 20·25
NPF
Group A 21 38 52 10 0·95 0·15
Group B 36 64 28 8 1·78
Fever
Group A 17 41 59 0 0·41 0·56
Group B 30 37 60 3 0·57
RSS
Group A 21 86 5 10 7·38 0·22
Group B 36 94 0 6 9·78
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to be a risk factor.12,35 However, the ratio we found could be the result of referral bias, with
more men being referred or coming to GPH&RC, and fewer women considered for treatment
with Thalidomide.
This study shows a long interval between the first symptoms of leprosy and the start of
MDT. The frequency of ENL-reaction might be reduced with timely diagnosis, lower
bacillary load, and adequate treatment.11 Van Brakel et al. showed that ENL was present in
30% of BL-LL cases at diagnosis.4 This was probably the reason for seeking health care.
In our study hospital registered group, 41% of patients developed ENL in the first 12 months
of taking MDT. Another study from Nepal had similar findings with 34% of patients
presenting with ENL before starting MDT and 45% developing it during the first 12 months
of taking MDT.11 A study from Ethiopia included 40 ENL-patients, of whom 9 (22·5%)
presented with ENL at the start of treatment, and 14 (35%) in the first year of MDT.13 A study
from north India reported that 20% of patients presented with ENL before starting MDT, and
that 30% developed ENL-reaction during the first year of taking MDT.12 Van Brakel et al.
conducted a study in Pokhara, Nepal, in 2004 and found a prevalence of 5·7% (10 of 175) in
BL/LL patients at registration and 3·2 ENL episodes per 100 person years at risk during
follow-up.4 In the AMFES-group in Ethiopia, all 16 ENL-patients developed ENL-reaction
after the start of MDT; the majority of cases first presented with ENL in the second and third
year after the start of MDT.9
In our study treatment of ENL was limited to 1 year in 33% of the cases. Kumar et al.
reported that 64·3% of all ENL-patients suffered from recurrent reaction and that treatment
duration averaged 34 months (range: 5 to 96 months).12 In the AMFES-group (Ethiopia), 63%
of all cases had more than one episode, and 31% developed five or more episodes over a
period of more than 2 years.9 In a study from Thailand, 34 (77%) of 44 ENL-patients had
multiple episodes with ENL.36 These results underscore the fact that ENL-reaction should be
regarded as a relapsing-remitting condition.
SYMPTOMS AND ORGAN INVOLVEMENT IN ENL-REACTION
At present, often only the typical ENL skin lesions are considered the main diagnostic
criterion of an ENL-reaction. Research on the first symptoms before the appearance of ENL-
lesions might be of clinical importance in order to help early diagnosis and improve treatment
outcome. Other highly prevalent symptoms such as NPF, NFI, fever and joint pain could be
helpful to improve early recognition and treatment of ENL in patients at risk.
Although ENL is widely known as a reaction with systemic symptoms in which many
organs may be involved, little is known about the incidence of these symptoms. In our study
the incidence of symptoms are extracted from the charts. Absence of notes on symptoms in
patients’ charts were considered negative findings, thus our data may underestimate
neuropathy. Symptoms may also have appeared due to side-effects of treatment, thus leading
to an overestimation in our study. For example, neuropathy may also occur as a side-effect of
thalidomide.20,22,23 There seems to be much more NFI in our study than would be expected.
This overestimation could be because NFI may have been recorded on the RSS as present
when patients reported to the hospital with NFI and it could not be established if this was
recent NFI due to ENL or ‘old’ NFI not necessarily related to ENL. No reliable data from
prospective studies are available on the possible progress of NFI in patients diagnosed with
lepromatous leprosy, with or without ENL.
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THALIDOMIDE IN ENL-TREATMENT
The two subgroups of ENL-patients had significant differences in severity of reaction,
duration of treatment, frequency of symptoms and organ involvement (Table 3). The presence
of certain symptoms may have been the reason for considering treatment with thalidomide.
We found that female patients were less likely to be treated with thalidomide than male
patients. This may be due to the clinician being unwilling to expose women to the risk of
phocomelia if they take thalidomide whilst in the early stages of pregnancy, although using
contraceptives protects women from this risk. Social factors such as an unwillingness to be
admitted may also decrease women’s access to thalidomide. The median age of the women in
our study was 35 (15–54). Most women were of child-bearing age and received ‘depot’
contraceptive treatment.
Figure 6 shows a significant difference in duration of treatment in both groups, which was
expected as group B is treated with thalidomide, indicative of a difficult-to-manage
ENL-reaction. The more severe ENL at start of treatment and higher high-scores in group B
indicates that patients presenting with severe ENL are at a higher risk of insufficient response
to prednisolone.
Table 5 shows no significant differences of treatment outcomes, but the difference in
outcome of NFI between RSS-item scores at the start and the end of treatment (improvement
of 0·52 point of the RSS in group A and worsening of 0·25 points in group B) may suggest a
worse NFI-outcome of nerve function in patients additionally receiving thalidomide
(P ¼ 0·07). This difference could be explained by the longer duration and more severe
ENL-reaction in group B, but also to neuropathy as a possible side-effect of thalidomide-
treatment.22
In our study, thalidomide was often prescribed in addition to prednisolone. Standard
treatment for severe ENL-reaction usually starts with 40 mg prednisolone. Longer duration
(low doses) is recommended for type 1 reaction leprosy reactions.20 We were not able
to compare prednisolone-treatment to thalidomide-treatment because the population of
both groups (thalidomide versus non-thalidomide) differed in many important variables.
In addition, many patients in both groups received additional drugs like pentoxyfillin,
cyclosporine or clofazimine.
Various studies support the use of thalidomide in ENL. It may reduce the need for steroids
and usually leads to quick improvement. Thalidomide has been shown to be more effective
than pentoxifylline.19 Treatment with inflixmab has been reported to be highly effective in a
case of recurrent ENL in which prednisolone, thalidomide and pentoxifylline failed.37
Azathioprine may also be a safe drug to prevent recurrence of ENL.38
LIMITATION OF THE STUDY
This was not a randomised clinical study comparing prednisolone with thalidomide (either
alone or together with prednisolone). In both groups patients sometimes also received other
drugs, especially in the ‘chronic’ ENL group e.g. clofazimine, cyclosporine or pentoxyfillin.
No firm conclusions can be made on the basis of our study and between the groups as group
assignment has also been influenced by the availability of thalidomide and/or presence of the
primary treating physician.
Lockwood summarised 4 double-blind studies that all showed benefits of thalidomide.20
But these studies were done more than 30 years ago. Patients were treated with different
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doses, for different lengths of time and different outcome measures were used. These patients
most likely also differed in the severity of ENL.
CONCLUDING REMARKS AND RECOMMENDATIONS
ENL-related symptoms like enlarged or painful nerves, NFI, fever, and arthralgia may help in
the early diagnosis of ENL and should be taken into account when making (sub) groups of
patients in order to investigate the efficacy of drug treatments.
In this study, male patients, and patients presenting with severe ENL-reaction were more
likely to receive thalidomide in addition to prednisolone.
There are no recently published high-quality randomised clinical studies on the
effectiveness of thalidomide in the treatment of ENL. Such studies are needed. There are also
no generally agreed recommended guidelines for the treatment of ENL as there are for the
treatment of reversal reaction. Further research is recommended to confirm and identify other
possible risk factors for the development of ENL. It is also recommended that in future
studies on ENL the Reaction Severity Scale is used to quantify severity of ENL (mild,
moderate, severe) and to follow patients in clinical trials.3,30
Further research is also recommended to be able to identify patients that may not
adequately respond to prednisolone.
We hope that our study will be helpful in the design of future studies looking into the
efficacy of thalidomide, and other drugs, in the treatment of (chronic) ENL. Based on our
study patient treatment groups should be, and can be better characterised with the use of the
RSS scale.
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Appendix. Reaction Severity Scale (please refer to van Brakel et al. Lepr Rev 2007, for recent version of Reaction Severity Assessment Form)30
Score 0 1 3 5
For type 1 reaction A1 Degree of inflammation of
skin lesion
None Erythema Erythema, raised lesion,
painful/plaques
Ulceration
A2 Number of inflamed
lesions
None 1 to 3 4 to 10 .10
For type 2 reaction A3 Degree of inflammation of
nodules
None Tender nodule(s) Painful nodule(s) Ulceration
A4 Number of nodules None #10 .10 .50/uncountable
A5 Inflammation of lymph
nodes due to current
reaction
None Chronic Mild, acute Definite
A6 Inflammation of joints due
to current reaction
None Chronic Mild, acute Definite
A7 Inflammation of eye due
to current reaction
None Chronic Mild, acute Definite
A8 Inflammation of testes due
to current reaction
None Chronic Mild, acute Definite
A9 Bone pain due to current
reaction
None Chronic Mild, acute Definite
For both type 1 and 2
reaction
A10 Fever due to reaction ,37·5 37·6–38·9 .39·0 –
A11 Peripheral oedema due to
reaction
None Oedema not affecting
function
Oedema affecting function –
A12 Number of limbs with
peripheral oedema due to
reaction
None 1 2 or more –
A13 Nerve pain None Mild, does not limit
activity
Sleep or activity disturbed Incapacitating
A14 Nerve tenderness on
gentle palpation
None Mild tenderness or
paraesthesia, absent if
attention is distracted
Present, even if attention
is distracted
Severe, patient withdraws
limb forcibly
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Appendix. continued
Score 0 1 3 5
A15 Degree of new nerve
enlargement (in nerves
previously known to be
normal)
No new enlargement or
borderline
Definite new enlargement – Nerve abscess
A16 Maximum sensory
impairment
None 1–2 levels lost 3–9 levels lost 9–15 levels lost
A17 Maximum motor
impairment
None (MRC 5) MRC 4 MRC 3 MRC , 3
A18 Number of nerves
showing recent motor or
sensory function
impairment
None 1 2 or 3 More than 3
RSS-score: cumulative of scores.
RSS-high score: cumulative of highest scores at any time during treatment.
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